Back to Search Start Over

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.

Authors :
Mirallas O
Filippi-Arriaga F
Hernandez Hernandez I
Aubanell A
Chaachou A
Garcia-Alvarez A
Hernando J
Martínez-Saez E
Biagetti B
Capdevila J
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Nov 11; Vol. 12, pp. 731631. Date of Electronic Publication: 2021 Nov 11 (Print Publication: 2021).
Publication Year :
2021

Abstract

Nelson's syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing's disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson's syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Mirallas, Filippi-Arriaga, Hernandez Hernandez, Aubanell, Chaachou, Garcia-Alvarez, Hernando, Martínez-Saez, Biagetti and Capdevila.)

Details

Language :
English
ISSN :
1664-2392
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
34858324
Full Text :
https://doi.org/10.3389/fendo.2021.731631